These data suggest that PCSK9 induces APC/KRAS-mutant CRC through the GGPP-KRAS/MEK/ERK pathway, and its targeting may be a therapeutic method in treating CRC (15, 156). This evidence concerns the gene KRAS and colorectal carcinoma.